ReviewWorld journal of surgical oncology2025
Primary pancreatic signet ring cell carcinoma: molecular mechanisms and advances in clinical diagnosis and treatment.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo comprehensively integrate current evidence on the molecular mechanisms, diagnostic approaches, and treatment options for primary pancreatic signet ring cell carcinoma (PPSRCC), guiding clinical decision-making and improving prognosis.
methodsIn addition to the narrative synthesis, we performed a targeted extraction and comparative synthesis of published patient-level cases, case series, and registry studies to generate pooled clinicopathologic summaries, propose an operational diagnostic workflow (imaging-EUS-FNA-IHC-molecular testing), and formulate PPSRCC-specific management recommendations.
resultsPrimary pancreatic signet ring cell carcinoma (PPSRCC) is a rare pancreatic cancer subtype with extremely high malignancy and very poor prognosis. Current research on this disease is limited with weak evidence, leading to insufficient clinical awareness. PPSRCC exhibits unique epidemiological characteristics, molecular mechanisms, and clinical diagnostic and therapeutic features. Molecular studies suggest that its carcinogenic pathways involve abnormal activation of the ErbB2/ErbB3-MUC4 axis, activation of the PI3K and MAPK pathways, and frequent mutations in classical pancreatic cancer driver genes such as KRAS; however, the lack of specific molecular biomarkers and typical imaging findings makes clinical diagnosis challenging. In terms of treatment, clinical practice mostly refers to the therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC), primarily surgery combined with radiochemotherapy. Targeted therapies against KRAS mutations and immunotherapy targeting PD-L1 may provide new directions for future management. In-depth elucidation of the molecular features of PPSRCC, clarification of diagnostic and therapeutic strategies, and development of novel targeted agents are key to improving clinical outcomes.
conclusionsDeeper mechanistic interrogation and standardized diagnostic workflows are needed to enable earlier detection and tailored therapy in PPSRCC. Multidisciplinary care and emerging precision strategies may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.